Milestones in Our History

April 1947	Hiroshi Tsuzuki (CEO) established the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen.
July	Injection Product for Neutropenia, "PANILTIN", sales launched
February 1949	Reishin Tanimura became the President.
June	Company head office relocated to Nishinari-ku, Osaka
September	Company head office relocated to Higashi-ku, Osaka. Manufacturing plant relocated to Ashiya-shi, Hyogo.
June 1951	Agreement for the sole distribution of Senju Products through Takeda Pharmaceutical Company Limited.
December 1955	Masao Yoshida became the President.
December 1958	Ophthalmic Solution for Cataract, "KATALIN", sales launched.
December 1962	Itami Plant established for manufacturing of ingredients in Itami, Hyogo.
April 1965	Artificial Tear Ophthalmic Solution, "MYTEAR", sales launched.
May	Company head office relocated to Kita-ku, Osaka
November 1969	Increase capital to 75,000,000 yen
March 1972	Company head office and Osaka branch are relocated to Hiranomachi, Higashi-ku, Osaka
April 1973	Capital increased to 150,000,000 yen
June 1974	Fukusaki Plant for manufacturing established in Kanzaki-gun, Hyogo
July	"Product for contact lens" sales launched
March 1978	Ophthalmic Solution for middle-aged persons, "VIDO-40", sales launched
June	Shoji Yoshida became the President.
November	Company head office relocated in Hiranomachi, Higashi-ku, Osaka.
February 1980	Ophthalmic Solution for exclusive use on contact lens, "MYTEAR CL", sales launched
September 1981	Penicillin Antibiotic Ophthalmic Product, "SULPELIN", sales launched
September 1983	Completion of Secondly Stage work on the Fukusaki Plant
November 1984	Ophthalmic Solution for Glaucoma, "MIKELAN 1%, 2%", sales launched
December 1985	Antifungal Ophthalmic Product, "PIMARICIN", sales launched
January 1987	Intraocular Irrigating Solution, "OPEGUARD MA",sales launched.
February 1988	Cephalosporin Antibiotic Ophthalmic Product, "BESTRON", sales launched
June	Capital increased to 1,415,500,000 yen
October	NSAID Ophthalmic Solution, "NIFLAN", sales launched
January 1993	Established resident office in Los Angels, California
February	Established Kobe Creative Center
July	Ophthalmic Viscoelastic Preparation, "OPELEAD", sales launched
April 2000	Antiallergic Ophthalmic Solution, "KETAS", sales launched
July	NSAID Ophthalmic Solution, "BRONUCK", sales launched
April 2001	Established the new laboratory in Oregon, USA
October 2003	NSAID Ophthalmic Solution, "MYTEAR EYETECT", sales launched
May 2004	Established resident office in Amsterdam, Netherland
September	4th Generation Fluoroquinolone Ophthalmic Solution, "GATIFLO", sales launched
April 2006	Established Senju U.S.A. INC. Established resident office in China, Beijing
June	Yukoh Yoshida became the President.
May 2008	Senju Medical Consulting (Shanghai) co., Ltd established in Shanghai, China.
	Ophthalmic Suspension for Spring Catarrh, "TALYMUS", sales launched
December	Construction of a New Plant begun in Karatsu, Saga
2009年1月	Allergy Containing Pranoprofen "Mytear EYETECT ALPITATTO", sales launched